Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Insights, news and analysis of the crypto market straight to your inbox ...

Using Bullish Candlestick Patterns To Buy Stocks Gauging the Strength of a Market Move Stochastics: An Accurate Buy and Sell Indicator Candlestick charts are a cornerstone in technical analysis ...

Leaders in the central Indian state of Madhya Pradesh, home to 72 million people, are considering punishing with the death penalty those who allegedly force people into religious conversion — a ...

The court’s decision to take up her challenge comes after the justices previously turned away opportunities to weigh in on conversion therapy bans. The case is set to be heard during the Supreme ...

Barcelona, Real Madrid and Atlético Madrid have all taken turns leading the Spanish top-flight this season and the table seems to change with every passing weekend. Real Madrid were the only team ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...